Biotech · Private company
Vironexis Biotherapeutics Inc.
Track this companyFree. Adds Vironexis Biotherapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials22 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- Dose Level 1, VNX-101Phase 2 · B-cell Acute Lymphoblastic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Dose Level 1, VNX-202Phase 2 · HER2 Expressing Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Dose Level 2, VNX-101Phase 2 · B-cell Acute Lymphoblastic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Dose Level 2, VNX-202Phase 2 · HER2 Expressing Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Dose Level 3, VNX-101Phase 2 · B-cell Acute Lymphoblastic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Dose Level 3, VNX-202Phase 2 · HER2 Expressing Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Dose Level 4, VNX-101Phase 2 · B-cell Acute Lymphoblastic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Dose Level 4, VNX-202Phase 2 · HER2 Expressing Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Gene Therapy for HER-Positive Cancer (SENTRY-HER2)PHASE1_PHASE2 · RECRUITING · started Nov 18, 2025ClinicalTrials.gov NCT07192432 · fetched Nov 12, 2026
- Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)PHASE1_PHASE2 · RECRUITING · started May 30, 2025ClinicalTrials.gov NCT06533579 · fetched Nov 12, 2026